Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic natural killer (NK) cell therapies for the treatment of cancer. The company operates within the cell therapy and immuno-oncology industries, with a primary emphasis on hematologic malignancies. Artiva’s core value proposition is leveraging NK cells derived from healthy donors and engineered for enhanced anti-tumor activity, aiming to deliver scalable, rapidly available therapies compared with autologous cell treatments.
The company was founded in 2019 and emerged from advances in NK cell biology and translational immunotherapy research. Artiva has positioned itself around combining allogeneic NK cell platforms with antibody-based therapies to enhance antibody-dependent cellular cytotoxicity. Its evolution has included the in-licensing of proprietary NK cell technology and the establishment of strategic collaborations to accelerate clinical development.
Business Operations
Artiva’s operations are centered on the research, development, and clinical advancement of its lead NK cell therapy candidates. The company’s primary business activities include preclinical research, clinical trials, manufacturing process development, and regulatory engagement. Revenue generation is not yet established, as Artiva remains in the clinical development stage with no approved commercial products as of the latest publicly available data.
The company’s lead programs include AB-101, an allogeneic NK cell therapy candidate designed to be used in combination with monoclonal antibodies, and AB-201, an engineered NK cell program incorporating enhanced persistence and activity. Artiva controls proprietary manufacturing and cryopreservation processes and has entered into notable partnerships, including a strategic collaboration with Roche to evaluate NK cell therapies in combination with Roche antibodies. Data inconclusive based on available public sources regarding additional subsidiaries or joint ventures beyond disclosed collaborations.
Strategic Position & Investments
Artiva’s strategic direction focuses on advancing off-the-shelf NK cell therapies through clinical proof-of-concept while differentiating on scalability, safety, and combination potential. Growth initiatives are centered on expanding clinical indications in hematologic cancers and exploring broader oncology applications through combination regimens. The company emphasizes rapid deployment and repeat dosing as competitive advantages relative to autologous cell therapies.
The company has completed multiple private financing rounds backed by institutional life sciences investors, supporting pipeline expansion and manufacturing capabilities. Artiva’s strategy includes continued investment in engineered NK cell technologies and cytokine support mechanisms to improve in vivo persistence. Data inconclusive based on available public sources regarding completed acquisitions or formal portfolio subsidiaries.
Geographic Footprint
Artiva Biotherapeutics is headquartered in the United States, with primary operations based in California. Its activities are concentrated in North America, where research, clinical development, and corporate functions are conducted. Clinical trials are primarily executed in U.S.-based clinical sites, with regulatory engagement focused on U.S. authorities.
While Artiva does not maintain broad international operations, its strategic collaborations and licensing arrangements give it indirect exposure to global oncology markets, particularly through partnerships with multinational pharmaceutical companies. Data inconclusive based on available public sources regarding permanent operational facilities outside the United States.
Leadership & Governance
Artiva is led by an executive team with experience in oncology drug development, biologics manufacturing, and corporate strategy. The leadership emphasizes scientific rigor, clinical translation, and partnership-driven growth to advance innovative immunotherapies efficiently and responsibly.
Key executives include:
- Fred Aslan – Chief Executive Officer
- Jeff S. Miller – Founder and Scientific Advisor
- Jill Carroll – Chief Business Officer
- Everett Cunningham – Chief Medical Officer
- Alex Leary – Chief Financial Officer
The company operates under a board-governed structure typical of venture-backed biotechnology firms, with oversight focused on clinical execution, capital allocation, and long-term value creation.